Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
关于控股股东、持股5%以上股东部分股份质押的公告
Regulatory Filings Classification · 35% confidence The document is an announcement by Enwei Pharma of a share pledge by its controlling shareholder and other >5% shareholders. It details the pledge amounts, terms, and cumulative pledge statistics. It is not an annual/interim report, earnings release, management discussion, or share repurchase. It’s not a share issuance, M&A, proxy, or remuneration statement. It’s a routine regulatory disclosure of a shareholder pledge event that doesn’t fit any more specific category, so it falls under General Regulatory Filings (RNS).
2026-05-25 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 93% confidence The document is an implementation announcement of the company’s 2025 profit distribution (cash dividend) plan, specifying dividend per share, record date, ex-dividend date, distribution methods, and related details. This is clearly a Notice of Dividend Amount, not a full report or other corporate action. Therefore, it falls under the DIV category.
2026-05-21 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2025年度持续督导培训情况的报告
Regulatory Filings Classification · 87% confidence The document is a report by the sponsor (中信证券) to the Shenzhen Stock Exchange on its 2025 ongoing supervision training of the listed company (恩威医药). It describes the training details, participants, and conclusions. It is neither an Annual Report, Interim Report, ESG report, nor any other specific category like capital update or dividend notice. It is a routine regulatory submission under exchange self-regulatory guidelines, without fitting a more specific filing type. Thus it falls into the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2026-05-20 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2025年度跟踪报告
Regulatory Filings Classification · 85% confidence The document is a detailed “跟踪报告” (track report) prepared by the IPO sponsor (中信证券) on Enwei Pharma’s 2025 annual follow‐up, covering information disclosure reviews, internal control checks, fundraising supervision, governance oversight, and regulator communications. It is neither an earnings release, interim report, annual report, nor any shareholder proposal or dividend notice. It constitutes a regulatory submission by the sponsor to the stock exchange/CSRC rather than a standard financial report or announcement of publication. Therefore it best fits the catch‐all Regulatory Filings category (Code: RNS).
2026-05-20 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2025年度持续督导定期现场检查报告
Regulatory Filings Classification · 85% confidence The document is a sponsor (“保荐机构”) continuous supervision periodic on-site inspection report for the 2025 year, detailing compliance checks on governance, internal control, disclosures, use of proceeds, etc. It is a regulatory compliance filing by the sponsor, not a financial report (10-K/IR/MDA) nor an audit certificate by auditors, nor an earnings release or investor presentation. It falls into the miscellaneous regulatory filings category.
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled “2025年年度股东会决议公告” and provides the results of votes on various proposals at the 2025 Annual Shareholders Meeting (AGM). It details attendance, vote counts (for, against, abstain) on each resolution, and the legal opinion confirming the meeting’s validity. This matches the definition of an announcement of voting results at a general meeting, which corresponds to the Declaration of Voting Results & Voting Rights Announcements category (Code: DVA).
2026-05-18 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.